Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Conventional), By Infection Type (UTI, Pneumonia), By Product (Consumables), By Type, By Region, And Segment Forecasts, 2023 - 2030

Hospital Acquired Infections Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Conventional), By Infection Type (UTI, Pneumonia), By Product (Consumables), By Type, By Region, And Segment Forecasts, 2023 - 2030


Hospital Acquired Infections Diagnostics Market Growth & Trends

The global hospital acquired infections diagnostics market is expected to reach USD 7.15 billion by 2030, according to a new report by Grand View Research, Inc. The global hospital acquired infections diagnostics market is projected to grow at a healthy CAGR of 7.2% during the period of 2023 to 2030. Factors attributing to the growth of the market are increase in the number of drug-resistant pathogens such as MRSA and C. difficile, advancing age of geriatric population, and development of technologically advanced products that offer accurate and reliable results with low turnaround time.

Another factor contributing to industry growth is the increasing demand of HAI diagnostics from middle and low income countries, further driving demand for HAI diagnostic market. Increasing awareness among healthcare workers and proposed government initiatives are further supporting industry growth. However, decline in the prevalence rate of nosocomial infections in the developed countries is likely to hinder industry growth.

The HAI diagnostics market is categorized on the basis of infection type and test type. On the basis of infection type, the market is segmented into Urinary Tract Infection (UTI), Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and others. As of 2015, the urinary tract infection segment was estimated to account for the largest share, whereas the pneumonia HAI diagnostics is projected to grow at the highest CAGR during the period of 2015 to 2022.The HAI diagnostics industry is further segmented into molecular tests and other in-vitro tests. Though the molecular diagnostics segment is estimated to constitute a low share, it is anticipated to witness a lucrative growth in the next few years.

Hospital Acquired Infections Diagnostics Market Report Highlights
  • The consumables segment held the largest revenue share of 63.5% in the hospital acquired infections diagnostics market in 2022 and is expected to expand at the fastest CAGR of 7.7% over the forecast period, owing to the rising incidence of HAIs.
  • The blood tests segment accounted for the largest revenue share of 65.8% in 2022 and is expected to advance at the fastest CAGR of 7.08% during the forecast period.
  • Europe dominated the market and accounted for the largest revenue share of 34.3% in 2022, owing to the high disease burden, the availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and the presence of major players.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Test Type
1.1.2. Infection Type
1.1.3. Product
1.1.4. Type
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test Type outlook
2.2.2. Infection Type outlook
2.2.3. Product outlook
2.2.4. Type outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Hospitals Acquired Infections Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Hospitals Acquired Infections Diagnostics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Hospitals Acquired Infections Diagnostics Market: Test Type Estimates & Trend Analysis
4.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
4.2. Hospital Acquired Infections Diagnostics Market: Test Type Movement & Market Share Analysis, 2022 & 2030
4.3. Conventional
4.3.1. Conventional market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Molecular
4.4.1. Molecular market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Hospital Acquired Infections Diagnostics Market: Infection Type Estimates & Trend Analysis
5.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
5.2. Hospital Acquired Infections Diagnostics Market: Infection Type Movement & Market Share Analysis, 2022 & 2030
5.3. UTI
5.3.1. UTI market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Pneumonia
5.4.1. Pneumonia market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Surgical Site Infection
5.5.1. Surgical site infection market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Blood Stream Infections
5.6.1. Blood stream infections market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Others infections market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Hospital Acquired Infections Diagnostics Market: Product Estimates & Trend Analysis
6.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
6.2. Hospital Acquired Infections Diagnostics Market: Product Movement & Market Share Analysis, 2022 & 2030
6.3. Consumables
6.3.1. Consumables market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Instruments
6.4.1. Instruments market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Hospital Acquired Infections Diagnostics Market: Type Estimates & Trend Analysis
7.1. Hospital Acquired Infections Diagnostics Market: Key Takeaways
7.2. Hospital Acquired Infections Diagnostics Market: Type Movement & Market Share Analysis, 2022 & 2030
7.3. Blood Tests
7.3.1. Blood tests market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Urinalysis
7.4.1. Urinalysis market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Hospital Acquired Infections Diagnostics Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. Hospitals Acquired Infections Diagnostics Market by Region: Key Takeaways
8.3. North America
8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.6. Denmark
8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.7. Sweden
8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.4.8. Norway
8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. BIOMÉRIEUX
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Abbott
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Siemens Healthcare Private Limited
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. BD (Becton, Dickinson and Company)
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Hologic, Inc.
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Meridian Bioscience, Inc.
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. QIAGEN
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Thermo Fisher Scientific Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Bioscience, Inc.
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings